Monitor the progress of CapsoVision's second-generation CapsoCam Colon capsule through FDA approval, as this will be critical for future revenue growth. The company's ability to secure additional financing will be important given the going concern qualification in the auditor's report. Watch for commercialization timelines for the AI-enhanced CapsoCam Plus and the colon capsule.
Executive Summary
CapsoVision is conducting a resale registration for 2.87 million shares issued in a private placement that raised $14 million. The company is a commercial-stage medical technology firm focused on capsule endoscopy for gastrointestinal diagnostics, with its CapsoCam Plus product generating $13.6 million in revenue in 2025. The company is developing an AI-enhanced second-generation colon capsule and faces risks related to FDA approval, competition, and its ability to continue as a going concern.
Key Financial Metrics
Key Facts
- Resale registration for 2,867,089 shares issued in a private placement at $4.883 per share, raising $14 million
- CapsoVision is a commercial-stage medical tech company focused on capsule endoscopy for GI diagnostics
- Generated $13.6 million in revenue in 2025 from CapsoCam Plus, up 15% from 2024
- Developing second-generation CapsoCam Colon capsule with improved imaging and AI capabilities, with FDA submission expected in Q3 2026
- Company has over 140 issued patents and raised $48 million in Series H preferred stock since 2022
- Auditor's report includes an explanatory paragraph regarding the company's ability to continue as a going concern
Financial Impact
The company raised $14 million in a private placement and has over $48 million in preferred stock issued since 2022. Revenue grew to $13.6 million in 2025 from $11.8 million in 2024.
Risk Factors
- FDA approval risk for the second-generation CapsoCam Colon capsule
- Going concern qualification in auditor's report indicating potential liquidity issues
- Competition from established players like Medtronic's PillCam COLON 2
- Dependence on successful commercialization of pipeline products for future growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001628280-26-025785 |
| Exhibit: exfilingfees.htm | 0001628280-26-025785 |
| Exhibit: exhibit51-sx1.htm | 0001628280-26-025785 |
| Exhibit: exhibit231-sx1.htm | 0001628280-26-025785 |
| Document: 0001628280-26-025785-index-headers.html | 0001628280-26-025785 |
| Document: 0001628280-26-025785-index.html | 0001628280-26-025785 |
| Document: 0001628280-26-025785.txt | 0001628280-26-025785 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $6.92 | awaiting T+60 | — | $6.89 (−0.43%) |
Sep 28, 2026 28d ago | Press Release | $6.92 | awaiting T+60 | — | $6.89 (−0.43%) |
Sep 23, 2026 4w ago | Insider Cluster | $6.17 | awaiting T+60 | — | $6.89 (+11.67%) |
Sep 22, 2026 4w ago | Institutional Cluster | $6.30 | awaiting T+60 | — | $6.89 (+9.37%) |
Sep 18, 2026 5w ago | 424B5 | $6.70 | awaiting T+60 | — | $6.89 (−2.84%) |
Aug 24, 2026 9w ago | EFFECT | $5.83 | awaiting T+60 | — | $6.89 (−18.18%) |
Aug 13, 2026 10w ago | S-3 | $6.46 | awaiting T+60 | — | $6.89 (−6.66%) |
Jul 21, 2026 13w ago | Insider Buy | $6.91 $6.45 | ▼ −6.66% | ▼ −9.92% | $6.89 (−0.29%) |
Jul 10, 2026 15w ago | Insider Buy | $6.22 $6.50 | ▲ +4.50% | ▲ +0.51% | $6.89 (+10.77%) |
Jul 7, 2026 15w ago | Insider Buy | $6.13 $6.32 | ▲ +3.18% | ▲ +0.69% | $6.89 (+12.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers